News

Filter

Current filters:

Anti-viralsRegulation

1 to 9 of 253 results

NICE recommends Sovaldi and Olysio for hepatitis C

NICE recommends Sovaldi and Olysio for hepatitis C

25-02-2015

The UK’s National Institute for Health and Care Excellence (NICE) has published final guidance recommending…

Anti-viralsGilead SciencesJanssenOlysioPharmaceuticalRegulationSovaldiUK

IQWiG sees benefits for Triumeq and Eperzan

05-02-2015

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) has announced its latest findings…

Anti-viralsDiabetesEperzanGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTriumeqViiV Healthcare

FDA approves Bristol-Myers Squibb's Evotaz in HIV-1

FDA approves Bristol-Myers Squibb's Evotaz in HIV-1

02-02-2015

US drug major Bristol-Myers Squibb has received approval from the US Food and Drug Administration for…

Anti-viralsBristol-Myers SquibbEvotazPharmaceuticalRegulation

Janssen's Prezcobix approved for HIV in the USA

Janssen's Prezcobix approved for HIV in the USA

30-01-2015

The US Food and Drug Administration has approved Prezcobix (darunavir 800mg/cobicistat 150mg) tablets,…

Anti-viralsJanssenPharmaceuticalPrezcobixRegulationUSA

EC approves AbbVie’s Viekirax + Exviera for hepatitis C

EC approves AbbVie’s Viekirax + Exviera for hepatitis C

16-01-2015

The European Commission has granted marketing authorizations for US drugmaker AbbVie’s all-oral, short-course,…

AbbVieAnti-viralsEuropeExvieraPharmaceuticalRegulationViekirax

UK NICE recommends hepatitis C drugs Sovaldi and Olysio

UK NICE recommends hepatitis C drugs Sovaldi and Olysio

16-01-2015

In final draft guidance issued today, England health costs watchdog the National Institute for Health…

Anti-viralsBiotechnologyGilead SciencesJanssenJohnson & JohnsonOlysioPricingRegulationSovaldiUK

Merck & Co updates on plans to accelerate new drug submissions and future growth

Merck & Co updates on plans to accelerate new drug submissions and future growth

13-01-2015

US pharma giant Merck & Co has reported on the ongoing execution of its multi-year, strategic initiative…

Anti-viralsgrazoprevir/elbasvirKeytrudaMerck & CoOncologyPharmaceuticalRegulationResearchUSA

ViiV’s Triumeq offers added benefit for treatment-naive adults with HIV, says IQWiG

ViiV’s Triumeq offers added benefit for treatment-naive adults with HIV, says IQWiG

08-01-2015

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTriumeqViiV Healthcare

1 to 9 of 253 results

COMPANY SPOTLIGHT

Menarini

Back to top